去纤维钠在治疗肝小静脉闭塞病这方面疗效怎么样？

(Alias: defibrotide) is the first drug approved by the US FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic venous obstruction (VOD) who have received blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or lung function abnormalities. The drug has also received "orphan drug" qualifications. Defibrinated sodium is not currently on the market in my country. Today we will mainly learn about the efficacy of defibrinated sodium in the treatment of hepatic veno-occlusive disease.

Defibrinated sodium is a mixture of single-stranded deoxyoligonucleotide sodium salts produced by controlled depolymerization of porcine intestinal mucosal genomic DNA. Its mechanism of action is complex and has not yet been fully elucidated. Medical Companion Travel has collected and compiled the following test data, which can more intuitively see the effect of defibrinated sodium.

The therapeutic effect of defibrinated sodium (defibrotide) was verified in three clinical trials. A total of 528 patients were included in the trials, all of whom were diagnosed with VOD symptoms after HSCT and were accompanied by abnormal liver or renal function. The overall survival rate 100 days after HSCT was used as the evaluation index. The results showed that the survival rate after 100 days for patients treated with defibrotide sodium was 38% to 45%; while data analysis found that the survival rate after 100 days for HSCT patients who were expected to receive only supportive care or other drug intervention was only 21% to 31%. In other words, treatment with defibrinated sodium can effectively improve the survival rate of patients.

Patients will have rare but often fatal complications after receiving chemotherapy and HSCT, and there is a relatively large demand for drugs in this area. The launch of (Defibrinoside) has filled this demand and brought new hope for the treatment of patients. As a new drug, defibrotide sodium has not yet been launched in my country. If patients need to purchase it, they can consult their medical companions.